Social Media Mythbusters: The Summer Skin Care "Shutdown"

From viral skin care hacks to trendy treatment devices, social media is shaping the questions patients bring into the exam room every day. In Dermatology Times’ new weekly series, Social Media Mythbusters, we break down trending claims clinicians are hearing in practice—exploring the proposed mechanism, what the evidence shows (or doesn’t), and whether each trend holds up under scrutiny.

In this edition, we’re examining the practice of halting the use of retinoids, chemical exfoliants, and other active ingredients in the summertime.

Have a social media trend you’d like us to investigate next? Send us the social media myths your patients are asking about, and we may feature them in an upcoming edition. Connect with us on our social media or email us at [email protected].

The Trend

Every spring, a wave of online content resurfaces: creators advising followers to pause retinoids, exfoliating acids, and sometimes an entire active-ingredient routine for the summer months, on the theory that these products "can't be used in the sun" or will cause severe burns, dark spots, or irreversible damage if UV exposure isn't eliminated. The advice is usually presented as a blanket seasonal rule—stop in May, resume in September—rather than a nuanced discussion of any single ingredient's actual photobiology.

The trend has real staying power because it contains a kernel of accurate pharmacology: several of the ingredients in question genuinely do interact with light and UV exposure in measurable ways. The problem is that "interacts with light" has been flattened into "must be discontinued," when the underlying data almost universally point toward a modification of use (better sun protection, evening application, dose titration) rather than cessation. For a subset of patients, most notably those using treatment for melasma, the seasonal shutdown is not just unnecessary but plausibly counterproductive, since UV exposure is itself the primary driver of the condition being treated.

Aleksandra Brown, DO, FAAD,(@draleksandrabrown)

The Mechanism

The retinoid-avoidance narrative conflates two distinct phenomena that share a superficial resemblance: photodegradation (the drug molecule itself breaking down under light) and photosensitivity (the skin becoming more reactive to UV as a result of drug exposure). Tretinoin is genuinely photolabile. It absorbs strongly in the UVA range and degrades on light exposure, which is the actual, well-established pharmacologic basis for the standard instruction to apply retinoids at night. Comparative photostability studies found that conventional lower-concentration tretinoin gel formulations lost the large majority of active drug within hours of solar-equivalent UVA exposure, while microencapsulated or micronized formulations were considerably more resistant to degradation under the same conditions.¹ This is a real, quantifiable effect, but it’s a statement about the drug's stability, not about the skin's safety in the sun.

Photosensitivity—true UV-induced skin reactivity caused by the drug—is a separate question, and the older but still-relevant phototoxicity literature on retinoids is notably reassuring. Controlled phototesting of subjects on oral isotretinoin found no clinical or phototest evidence of photosensitivity in the majority of subjects studied, with in vitro photohemolysis data suggesting a phototoxic potential exists for tretinoin and isotretinoin under laboratory conditions but translating into clinical photosensitivity only idiosyncratically in vivo.² The more common phenomenon patients and clinicians observe—a subjectively "sun-sensitive" feeling—is more consistent with retinization-related barrier thinning and vasodilation than with a classic drug-induced photosensitivity reaction.

Unlike the retinoid case, the sun-sensitivity concern with alpha hydroxy acids (AHAs) has direct regulatory backing. FDA's review of the AHA safety literature concluded that topically applied AHAs increase skin's sensitivity to UV radiation during use, with human trial data showing an average increase in UV sensitivity and a roughly twofold increase in sensitivity to UV-induced cellular damage after several weeks of use—findings substantial enough that FDA guidance recommends a "Sunburn Alert" label on AHA-containing cosmetic products. Critically, the same body of evidence also found the effect to be reversible: increased UV sensitivity diminishes within about a week of discontinuing the product, and it does not translate into any established photocarcinogenicity signal.³

This is the one ingredient category in the trend with a real, quantified, agency-recognized photosensitizing mechanism—which is precisely why it deserves to be discussed on its own terms rather than folded into a blanket "actives off in summer" rule that then gets applied, without evidence, to retinoids and pigment agents that don't share the same mechanism.

The Evidence

The clinical cost of a multi-month treatment interruption is measurable and is not restricted to a "summer glow" trade-off. For acne patients maintained on topical retinoids after completing oral isotretinoin, each additional month of continued topical retinoid maintenance was associated with a substantially lower probability of relapse, underscoring that topical retinoid therapy functions as ongoing disease control rather than a course that can be safely interrupted without consequence.⁴ Photoaging-oriented retinoid use follows a similar logic: the collagen-synthesis and turnover benefits that retinoids produce accrue over months of consistent use and are not preserved through a several-month interruption. A 4-to-6-month "off" season for a 12-month annual routine represents a meaningful fraction of the therapeutic exposure window being forfeited for a photosensitivity concern that, for tretinoin specifically, has weak clinical support.

Across all active ingredient categories, the actual evidence-based mitigation is the same: broad-spectrum sunscreen, reapplication, and sensible sun-exposure behavior—not discontinuation. FDA's own AHA guidance frames the recommended consumer action as sunscreen use and limited sun exposure during treatment and for roughly a week afterward, not months-long avoidance. The retinoid literature's consistent instruction is evening application plus daytime SPF, a regimen most patients are (or should already be) following for reasons entirely independent of retinoid use. In other words, the intervention the trend proposes (stopping the active ingredient) is not the intervention the underlying data actually support (applying it correctly and protecting the skin around it). The claim that all "actives" share a uniform sun-reactivity profile is not supported. And the trend does not account for the treatment cost of interruption: months of lost maintenance benefit for acne and photoaging, and lost ground against a condition like melasma that the summer sun is actively working to worsen.⁵

Derrick Phillips, MBBS BSc, FRCP(@drderrickphillips)

The Verdict

Is this a myth? Yes!

The blanket "stop your actives in summer" framing does not hold up ingredient by ingredient. Retinoids can and should generally continue year-round with standard evening application and daily sunscreen; the photosensitivity concern driving much of this trend has limited clinical support for tretinoin and its relatives. AHAs/BHAs are the one category with a genuine, FDA-documented UV-sensitizing effect. But the evidence-based response is sunscreen and judicious use, not necessarily full discontinuation, and the effect reverses quickly once use stops if a patient does choose a break. Hydroquinone and other pigment-modifying agents are the clearest case where the trend gets the direction backwards: melasma is a UV-driven condition, and any legitimate rationale for pausing hydroquinone rests on cumulative-duration ochronosis risk, not on summer sun exposure itself.

The clinically useful message is not "keep going, ignore the sun" or "stop everything for the season.” Each ingredient has a different relationship to UV exposure, and the correct response in every case is better photoprotection paired with the active, not a several-month gap in a treatment plan that was working.

The Script

If a patient comes in planning to stop their active ingredient use in the summer months, here are some important points to hit:

• Maintain the retinoid routine: Stopping for months means reduced benefit, so apply at night and wear sun protection during the day, as usual.
• Pay special attention to patients with melasma: With melasma being driven by UV exposure, this is arguably the worst time of year to be stopping treatments like hydroquinone.
• Emphasize SPF: Daily sunscreen is essential, no matter what ingredients are used, but it’s particularly noted by the FDA for AHA/BHA exfoliant products.
• Simplify other products in the routine: Keep the retinoids, prescriptions, and other actives, but maybe opt for lighter textures of moisturizer and sunscreen.

References

1. Del Rosso JQ, Harper J, Pillai R, Moore R. Tretinoin photostability: comparison of micronized tretinoin gel 0.05% and tretinoin gel 0.025% following exposure to fluorescent and solar light. J Clin Aesthet Dermatol. 2013;6(2):25-28.

2. Ferguson J, Johnson BE. Photosensitivity due to retinoids: clinical and laboratory studies. Br J Dermatol. 1986;115(3):275-283. doi:10.1111/j.1365-2133.1986.tb05742.x

3. US Food and Drug Administration. Guidance for Industry: Labeling for Cosmetics Containing Alpha Hydroxy Acids as Ingredients. Rockville, MD: US Department of Health and Human Services; 2005. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-labeling-cosmetics-containing-alpha-hydroxy-acids

4. Morales-Cardona CA, Sánchez-Vanegas G. Acne relapse rate and predictors of relapse following treatment with oral isotretinoin. Actas Dermosifiliogr. 2013;104(1):61-66. doi:10.1016/j.ad.2012.05.004

5. Sarkar R, Sahu A. Role of Antioxidants in Melasma: A Systematic Review. Indian J Dermatol. 2025;70(3):125-134. doi:10.4103/ijd.ijd_473_24